Literature DB >> 6205341

On the pathogenesis of diabetic retinopathy.

R N Frank.   

Abstract

Recent investigations of retinal vascular cells in tissue culture, animal models, and diabetic human subjects suggest several potential pathogenetic mechanisms for diabetic retinopathy. These include the enzyme aldose reductase, which appears to be responsible for basement membrane thickening in galactosemic rats (since the lesion is prevented by an aldose reductase inhibitor), and a picture, in galactosemic dogs, that closely resembles early, background diabetic retinopathy; insulin, which stimulates, and elevated glucose levels, which inhibit in vitro proliferation of retinal pericytes. Various hormones, including the sex hormone, the insulin-like growth factors and, perhaps independently, growth hormones, may influence the later stages of diabetic retinopathy. Chronic hyperglycemia appears to be the primary pathogenetic agent in diabetic retinopathy as well as in other complications of diabetes, but the different rates of onset and progression of these complications suggest that glucose acts through different biochemical pathways that are probably under different genetic control. Finally, the locus of the primary biochemical lesion in diabetic retinopathy may reside in the neuronal or glial cells of the retina, with the retinal blood vessels only secondarily involved.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6205341     DOI: 10.1016/s0161-6420(84)34258-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  22 in total

Review 1.  A multifocal electroretinogram model predicting the development of diabetic retinopathy.

Authors:  Marcus A Bearse; Anthony J Adams; Ying Han; Marilyn E Schneck; Jason Ng; Kevin Bronson-Castain; Shirin Barez
Journal:  Prog Retin Eye Res       Date:  2006-09-01       Impact factor: 21.198

2.  A non-mammalian in vivo model for cellular and molecular analysis of glucose-mediated thickening of basement membranes.

Authors:  X Zhang; J K Huff; B G Hudson; M P Sarras
Journal:  Diabetologia       Date:  1990-11       Impact factor: 10.122

3.  Diabetic eNOS-knockout mice develop accelerated retinopathy.

Authors:  Qiuhong Li; Amrisha Verma; Ping-Yang Han; Takahiko Nakagawa; Richard J Johnson; Maria B Grant; Martha Campbell-Thompson; Yagna P R Jarajapu; Bo Lei; William W Hauswirth
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-30       Impact factor: 4.799

4.  A three-pore model describes transport properties of bovine retinal endothelial cells in normal and elevated glucose.

Authors:  Sandra V Lopez-Quintero; Xin-Ying Ji; David A Antonetti; John M Tarbell
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-28       Impact factor: 4.799

5.  Non-retinovascular leakage in diabetic maculopathy.

Authors:  D Weinberger; S Fink-Cohen; D D Gaton; E Priel; Y Yassur
Journal:  Br J Ophthalmol       Date:  1995-08       Impact factor: 4.638

6.  Presence and further development of retinal dysfunction after 3-year follow up in IDDM patients without angiographically documented vasculopathy.

Authors:  M A Di Leo; S Caputo; B Falsini; V Porciatti; A V Greco; G Ghirlanda
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

7.  Disappearance and formation rates of microaneurysms in early diabetic retinopathy.

Authors:  T Hellstedt; I Immonen
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

8.  The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy.

Authors:  A Tromp; J M Hooymans; B C Barendsen; J J van Doormaal
Journal:  Doc Ophthalmol       Date:  1991       Impact factor: 2.379

9.  Pancreatic islet allograft prevents basement membrane thickening in the diabetic rat retina.

Authors:  A A Sima; S Chakrabarti; W J Tze; J Tai
Journal:  Diabetologia       Date:  1988-03       Impact factor: 10.122

10.  Diabetes-induced dysfunction of retinal Müller cells.

Authors:  Donald G Puro
Journal:  Trans Am Ophthalmol Soc       Date:  2002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.